Futura Medical plc (AIM: FUM) (the “Company”), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology and currently focused on sexual health and pain, is pleased to announce a joint venture collaboration with CBDerma Technology Limited to explore the application of Futura’s advanced proprietary transdermal drug delivery technology, DermaSys® for delivery of Cannabidiol. All Intellectual Property will be owned jointly by the Company and CBDerma Technology Limited.
CBDerma Technology is a company that has been established and funded to specifically exploit the therapeutic potential of Cannabis. The company’s management, backers and advisors have extensive knowledge, expertise and investments in plant derived product manufacturing. Cannabidiol is a major component of the cannabis plant and is generally regarded as non-addictive and non-psychoactive, making it ideal for consideration as a topically delivered molecule for local or regional (non-systemic) use.
Initial development costs are expected to be in the region of US$ 1 million and will cover all development costs incurred by the Company during the next 15 months in order to develop and optimise a DermaSys®- cannabidiol formulation as well as establishing early ex-vivo proof of concept studies likely to include certain disease states most suited for local or regional (non-systemic) topical treatment such as pain relief. The Company does not expect this project’s initial development to have any material impact on cashflow as Futura’s financial share of the project will be delivered from its expertise and existing internal resources.
DermaSys® provides rapid and targeted local delivery of active pharmaceutical ingredients at therapeutic levels through the skin to the required site of action with a high level of safety. It is a versatile and bespoke technology that can be tailored to suit the specific active compound being used and the therapeutic indication. Each product is formulated to maximise its benefits for patients and consumers and can be developed for the prescription and consumer healthcare markets as appropriate.
James Barder, CEO of Futura Medical said: “Futura’s core strength lies in our research and development capabilities, particularly in the application of our proprietary Dermasys® transdermal delivery system which enables targeted and controlled delivery of drugs through the skin. The benefits and applications of cannabis and cannabidiol in both the medical and consumer markets are well known and expanding rapidly. However, optimised and targeted topical delivery of the active ingredients remains a problem. We believe that our Dermasys® technology has the potential to solve these issues, advancing product development and expanding indications and use of Cannabidiol.”
About Futura Medical plc
Futura Medical plc (AIM: FUM), is a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal Dermasys® drug delivery technology. These products are optimised for clinical efficacy, safety, administration and patient convenience and are developed for the prescription and consumer healthcare markets as appropriate. Current therapeutic areas are sexual health, including erectile dysfunction, and pain relief. Development and commercialisation strategies are designed to maximise product differentiation and value creation whilst minimising risk.
The first European Phase 3 study for MED2005, referred to as “FM57”, is a 1,000 patient, dose-ranging, multi-centre, randomised, double blind, placebo-controlled, home use, parallel group study of MED2005 0.2%, 0.4% and 0.6% Glyceryl Trinitrate for the treatment of erectile dysfunction with an open label extension. FM57 is progressing on track, with headline data expected by the end of 2019.
Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange. www.futuramedical.com
Futura Medical（AIM:FUM）（以下简称“公司”）是一家制药公司，基于其专有的经皮Dermasys®药物递送技术开发一系列创新产品，目前专注于性健康和性疼痛，很高兴宣布与ITH CBderma Technology Limited将探索Futura先进的专有透皮给药技术Dermasys®在给药Cannabidiol中的应用。所有知识产权将由公司和CBderma科技有限公司共同拥有。
futura medical首席执行官詹姆斯巴德（james barder）表示：futura的核心优势在于我们的研发能力，特别是我们专有的dermasys透皮给药系统的应用，该系统允许药物通过皮肤有针对性地、有控制地给药。大麻和大麻比妥尔在医疗和消费市场的益处和应用是众所周知的，并迅速扩大。然而，优化和有针对性的局部递送活性成分仍然是一个问题。我们相信，我们的Dermasys技术有潜力解决这些问题，促进产品开发，扩大适应症和cannabidiol的使用。
futura medical plc（aim:fum）是一家制药公司，基于其专有的经皮皮肤给药技术开发一系列创新产品。这些产品针对临床疗效、安全性、给药和患者方便性进行了优化，并根据需要为处方药和消费者健康市场开发。目前的治疗领域是性健康，包括勃起功能障碍和疼痛缓解。开发和商业化战略旨在最大化产品差异化和价值创造，同时最小化风险。